Savara (NASDAQ:SVRA) Sets New 1-Year Low Following Analyst Downgrade

Savara Inc. (NASDAQ:SVRA – Get Free Report) hit a new 52-week low on Friday after HC Wainwright lowered their price target on the stock from $10.00 to $9.00. HC Wainwright currently has a buy rating on the stock. Savara traded as low as $4.00 and last traded at $4.4320, with a volume of 4,158,457 shares traded. The stock had previously closed at $5.21.

Several other equities analysts have also issued reports on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 target price for the company. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Citigroup reiterated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Finally, Royal Bank Of Canada set a $10.00 price objective on Savara in a report on Wednesday, October 7th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Get Our Latest Report on Savara

Top Savara Stories

Here are a few of the latest stories about SVRA:

  • Positive Sentiment: HC Wainwright maintained a Buy rating while lowering its price target from $10 to $9, still implying substantial potential upside from the quoted share price. HC Wainwright rating
  • Negative Sentiment: The FDA told Savara it would not act on the molgramostim BLA by the PDUFA date. The missed review deadline is the key near-term negative catalyst, postponing regulatory clarity for the drug candidate. Savara FDA update Reuters report

Institutional Investors Weigh In On Savara

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Savara during the second quarter worth $76,966,000. Nantahala Capital Management LLC grew its holdings in Savara by 2.3% in the third quarter. Nantahala Capital Management LLC now owns 7,137,159 shares of the company’s stock valued at $36,828,000 after purchasing an additional 160,349 shares during the last quarter. Marshall Wace LLP increased its position in shares of Savara by 2.1% in the third quarter. Marshall Wace LLP now owns 6,386,775 shares of the company’s stock valued at $32,956,000 after buying an additional 129,786 shares in the last quarter. Spruce Street Capital LP purchased a new position in shares of Savara in the second quarter valued at $21,267,868. Finally, Nan Fung Trinity HK Ltd. raised its stake in shares of Savara by 1,088.3% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after buying an additional 1,687,310 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Down 18.2%

The firm has a market cap of $939.86 million, a price-to-earnings ratio of -6.98 and a beta of 0.32. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average price of $4.86 and a 200-day moving average price of $5.31.

Savara (NASDAQ:SVRA – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. On average, equities analysts forecast that Savara Inc. will post -0.67 EPS for the current year.

About Savara

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Read More

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.